GENETIC CURES THROUGH

TRANSFORMATIVE SCIENCE

Lacerta Therapeutics is dedicated to the discovery and development of AAV-based gene therapies. We aim to provide novel therapeutic options by leveraging our expertise in the nervous system, proprietary AAV capsid technologies and scalable manufacturing platforms across three modalities: gene replacement, vectorized antibody delivery and artificial microRNA-mediated modulation of gene expression.

Programs & Pipeline
Science & Technology
24x7 We are available

Call Us

Aenean neque justo, molestie vitae nec,
consequat scelerisque metus.

Call (386) 518-6424

Headquarters

14189 NW 129th Way
Alachua, FL 32615
info@lacertatx.com

Business Hours

Monday - Friday
8:00am - 7:00pm
Saturday
10:00am - 5:00pm
Sunday
10:00am - 3:00pm

Our Story

Welcome toLacerta Therapeutics

In 2017, the stars truly aligned when a group of University of Florida faculty, with unmatched expertise & experience in the development, production, and application of gene therapies, founded Lacerta Therapeutics. Driven to discover and develop treatments for the central nervous system and lysosomal storage diseases through proprietary adeno-associated virus (AAV) vector technologies, Lacerta has quickly become a nationally recognized partner in the development of genetic-based medicines & treatments for central nervous system and lysosomal storage diseases.

Programs

Team Members

Patents

Years of Experience

Read More

Our Programs

Transformative Science

Our therapeutic programs are focused on exploiting our proprietary capsid technology and scalable manufacturing platform to advance AAV-based therapies via three primary approaches: gene replacement, vectorized antibody, and vectorized micro-RNA modulation. Our state-of-the-art manufacturing platform supports a robust & growing therapeutic pipeline. New partnerships & collaborations are enabling us to advance the development of AAV gene therapies for patients.
o

MPSIIIB

Also known as Sanfilippo Syndrome B, is a disorder caused by mutations in the NAGLU gene.

o

Pompe Disease

Pompe Disease is a genetic disorder that is caused by a mutation in the GAA gene.

o

Friedreich's Ataxia

Rare mitochondrial disorder caused by mutations in the FXN gene.

o

Glioblastoma (GBM)

Glioblastoma is the most common and aggressive cancer of the brain.

Find Out More About Our Research!

We believe it is possible to develop gene therapies to treat diseases affecting the CNS in our lifetime! Our proprietary AAV technology enables us to advance therapies with higher precision and meet the demands of scalable manufacturing platforms.
Contact Us
Science & Technology

Visionary Gene-Based Solutions Fueled By Innovative Manufacturing Technologies

Lacerta Therapeutics is deploying proprietary AAV capsid variants and a state-of-the-art manufacturing platform to support its growing therapeutic pipeline. These innovative technologies are available for licensing, and we are aggressively seeking partnerships to further enable the development of AAV gene therapies for patients.
Learn More

AAV CAPSID ENGINEERING PLATFORM

Lacerta Therapeutics has established an innovative AAV capsid engineering platform that combines rational design and combinatorial libraries approaches to derive novel AAV capsid variants for our CNS and lysosomal storage disease applications.

AAV VECTOR MANUFACTURING PLATFORM

Lacerta Therapeutics has developed a robust AAV vector manufacturing platform using next-generation stable packaging and producer insect cell lines to generate high AAV vector yields using a single baculovirus (OneBac).

Our Team

Meet Our Leadership

EDGAR RODRIGUEZ, PHD

President and CEO

DARIN FALK, PHD

Chief Scientific Officer

AMY GRIFFIN

VP of Operations

KENNETH WARRINGTON, PHD

Chief Technology Officer

SHANNON WILSON, MBA

Senior Director of Finance

Meet More of our Team

Our Blog

Latest News & Articles

View More Articles